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Abstract. Decreased delayed recall, decreased amyloid-β peptides (Aβ1−42), and increased tau protein concentration in cere-
brospinal fluid (CSF) are generally regarded to be valid neuropsychological and biological markers for Alzheimer’s disease
(AD). Previous studies failed to demonstrate clear-cut correlations between neuropsychological impairment and CSF markers.
In this study we test recent models of disease progression, that propose that changes in CSF biomarkers already reach a plateau
in a preclinical phase, before cognitive decline begins, that is, even before MCI can be diagnosed. We recruited 73 patients
with probable AD (n = 36) and mild cognitive impairment (MCI) (amnesic MCI = 25; non-amnesic MCI = 12). We used
the CERAD-NP, a widely used neuropsychological battery with norms for different age and education groups, and additional
neuropsychological tests for assessing the cognitive profile of these patient groups. We found a significant correlation between
Aβ1−42 in the CSF and memory performance for amnesic MCI patients, but not for non-amnesic MCI and AD patients. All other
correlations between cognitive tasks and Aβ1−42 were not significant. Tau protein concentration in the CSF was not correlated
with any neuropsychological marker in any of the patients groups. We conclude that the decrease of Aβ1−42 in the CSF mirrors
disease progression during the early stages up into AD and therefore is not restricted to the preclinical phase. The decrease of
Aβ1−42 reaches a plateau only in the full blown demented syndrome and further functional disease progression is then related to
neurodegeneration without further reduction of Aβ1−42 in the CSF.
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INTRODUCTION
Cortical and limbic accumulation of intraneuronal
neurofibrillary tangles (NFT) and extracellular amyloid
plaques are the two main diagnostic neuropathological
features of Alzheimer’s disease (AD); other prominent
changes include neuronal loss, synaptic loss, and glio-
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Germany. Tel.: +49 421 408 1599; Fax: +49 421 408 2599; E-mail:
helmut.hildebrandt@uni-oldenburg.de.
sis. According to the amyloid cascade hypothesis of
Hardy and Selkoe, accumulation of amyloid-β peptides
(Aβ) in the brain as a result of genetic mutations in
the AβPP gene is the primary mechanism driving AD
pathogenesis [1,2]. Progression of the disease, includ-
ing formation of neurofibrillary tangles containing tau
protein, has been proposed to result from an imbal-
ance between Aβ production and Aβ clearance. The
relevance of the amyloid hypothesis has been ques-
tioned for the much more frequent multifactorial spo-
radic form of AD. In some studies, a correlation has
been found between elevated levels of Aβ in the brain
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and cognitive decline [3], but the quantity of amyloid
deposits does not seem to correlate well with the de-
gree of cognitive impairment. Several studies have re-
ported patients without overt symptoms of dementia,
yet showing many amyloid deposits in the brain at au-
topsy [4]. Given the pathologic changes in the AD
brain, including accumulation of neurofibrillary tan-
gles and Aβ, reduced levels of synaptophysin, and el-
evated levels of glial fibrillary acidic protein (GFAP),
Ingelsson and colleagues compared neuropathological
changes in the temporal association cortex of AD cas-
es with varying disease duration, with those of control
brains, in an attempt to define the time course of these
changes [5]. The two main findings of this study were:
1) Accumulation of Aβ was markedly increased in AD
brains, independent of disease duration; and 2) The du-
ration of dementia correlated with the degree of tan-
gle formation, gliosis, and synaptic loss, but not with
any of the Aβ measures. Ingelsson et al. [5], and later
Jack et al. [6], therefore postulated that the pathological
changes in AD occur in a sequential, neuroanatomical-
ly defined pattern, affecting cortical, subcortical, and
limbic regions.
According to this view, the beginning of Aβ-
production and plaque formation antedates the clini-
cal course of AD for years, and accelerates in an early
phase, during a preclinical state, in which clinical or
neuropsychological changes are not yet demonstrable.
Aβ deposition appears to be already at a ceiling level
when patients progress into clinical mild cognitive im-
pairment (MCI) and into the dementia syndrome prop-
er. At this stage of the disease, NFT formation, increas-
ing gliosis, and progressive neuronal loss are initiated
and continues into the clinical state of the full blown
dementia. Therefore, Aβ concentration already has
reached a steady state before an affected patient shows
even MCI and the concentration of tau has increased
over 50%, compared to the healthy status [6]. This
would explain why the correlation between these CSF
markers and neuropsychological test scores is low in
that phase or even not demonstrable,because when cog-
nitive deterioration starts, CSF markers have already
reached a plateau.
As Jack et al. [6] correctly state, the earliest and core
symptom of AD is an episodic memory deficit, which
exacerbates during the preclinical period [7], and is ac-
companied by increasingly severe disturbances in lan-
guage, attention, executive functions, and mood in later
phases of the disease [8,9]. More specifically, AD is
characterized by an impairment in delayed recall, and
several studies have shown that this impairment is a
sensitive and partly specific feature of patients convert-
ing from MCI to AD [10–13]. Patients with amnesic
cognitive impairment are more likely to represent an
early stage of AD than patients with non-amnesic cog-
nitive impairment [14]. Therefore, the earliest phase
of AD neuropsychological testing should be focused
on learning tests and on recall of learned information
after a delay or following interfering materials [7,15,
16]. But the few studies, that have been published up
to now on the correlation between CSF markers and
cognitive decline, often relied on cognitive tests that
are rather insufficient for this purpose, like the Mini
Mental Status Examination (MMSE) [17–20]. This in-
strument yields a composite score of cognitive impair-
ment and is rather insensitive to mild impairment. This
may be the reason why these studies found negative or
mixed results. Ivanoiu & Sindic [21], using an extend-
ed neuropsychological battery, reported that a low level
of Aβ1−42 (but not of tau) predicts a conversion to AD.
Stomrud and collaborators [17] showed that a low level
of Aβ1−42 is correlated with a decline in the MMSE
score three years later in healthy elderly subjects. We
have also found that Aβ1−42 and not tau protein corre-
lates with memory functions [22]. This would suggest
that Aβ1−42 still declines in CSF during the clinical
phase of amnesic MCI, which would be highly relevant
for the early identification of AD patients.
From the models of Jack et al. [6] and Ingelson et
al. [5], two predictions can be derived: 1) Aβ1−42 con-
centration in the CSF should correlate with memory
performance, but not with other cognitive functions, in
preclinical AD patients (i.e., patients still without cog-
nitive impairments), while there is no such correlation
in MCI and AD patients; and 2) Tau protein concentra-
tion should correlate with severity of dementia in the
period when the disease progresses into the dementia
syndrome, but not in the preclinical stage and in clinical
MCI.
MATERIALS AND METHODS
Patients
We recruited 73 patients with a cognitive impair-
ment, admitted to the neurological department of our
hospital over the last years. They were investigated
with respect to a diagnosis of cognitive disorder. Pa-
tients with definite other causes for their cognitive im-
pairment, like inflammation or acute stroke, were ex-
cluded from the analysis. See for demographic details
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Table 1
Demographic data, Mini Mental Status Examination (MMSE), Becks depression inventory
(BDI), CSF marker
AD amn-MCI n-amn-MCI
n 36 25 12
f/m 23/13 9/16 5/7
Mean SD Mean SD Mean SD
Age (y) 70.1 9.2 70.0 7.6 64.8 7.8
Education (y) 12.9 3.5 13.1 2.8 12.3 1.9
BDI 6.9 7.0 11.7 8.7 10.0 8.1
MMSE (raw values) 17.5 5.7 25.9 1.7 27.0 2.0
Tau-protein (ng/l) 665 469 415 299 285 143
Aβ1−42(ng/l) 469 235 661 323 813 289
Abbreviations: AD = Alzheimer’s disease, amn-MCI = amnesic mild cognitive impairment,
n-amn-MCI = non-amnesic mild cognitive impairment, BDI = Beck Depression Inventory,
MMSE = Mini Mental Status Examination, SD = Standard deviation.
Table 1. Recruitment was done as part of a prospec-
tive study on neuropsychological and biomarkers for
differential diagnosis in dementia, which is still run-
ning and ultimately seeks to determine the significance
of MRI based atrophy measurement and serum/CSF
markers for explaining neuropsychological decline in
these patient groups. The project was approved by the
Ethics committee of the University of Oldenburg, and
all subjects gave informed consent to participate in the
project.
Neuropsychological investigation
All patients underwent a neuropsychological exam-
ination, including the German Version of the CERAD
test battery [23–27], which is composed of the MMSE,
a 15-item short version of the Boston Naming Test, se-
mantic word fluency test for animals (one minute),word
list learning (10 words, three trials), word list recall
after distraction, word list recognition (10 target and 10
distractor words), figure copying and delayed figure re-
call. For additionally testing, we used the first-letter flu-
ency test from the Leistungspru¨fsystem 50+ test [28],
which is a German version of the FAS test (generation
of words starting with these letters for 1 minute), the
Mehrfachwahl-Wortschatz-Intelligenztest [29], which
was used as a measure for extent of and access to the vo-
cabulary, the Zahlenverbindungstest of the Nu¨rnburger
Alters Inventar [30], which is similar to the Trail Mak-
ing Test A, and the digit span forwards and backwards
from the German version of the Wechsler Memory
Scale [31], to investigate verbal working memory per-
formance. The Beck Depression Inventory (BDI) [32]
was used to assess mood and depression.
Neurological investigation
The neurological investigation included medical his-
tory, physical and neurological examination, labora-
tory blood sample testing, brain imaging, electroen-
cephalography and a lumbar puncture for the determi-
nation of Tau protein and Aβ1−42 levels.
The blood sample analysis included blood count,
erythrocyte sedimentation rate, electrolytes (sodium,
potassium, chloride), creatine, urea, transaminases,
blood glucose, TSH, C-reactive protein, vitamin B12,
folic acid. Optional additional blood analyses included
vitamins, TPPA, immunological parameter, HIV, cop-
per metabolism, etc. An MRI or CT scan was per-
formed for every patient to exclude other causes for
cognitive impairment like stroke, tumor, or an inflam-
matory disease.
Clinical diagnosis
The clinical diagnosis of AD or MCI was based
on best clinical judgment, based on the ICD 10 [33]
and the guidelines of the German Neurological So-
ciety for diagnosing AD. The German guidelines are
based on the criteria of the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-IV) [34]
and the National Institute of Neurological Disorders
and Stroke-Alzheimer’s Disease and Related Disor-
ders (NINCDS-ADRDA) working group [35,36], but
not fully identical with these (http://www.dgn.org/-
leitlinien-online.html). For example, according to the
NINCDS-ADRDA-criteria, the diagnosis of a probable
AD is possible without impairment of daily life activi-
ties, although it is necessary for the diagnosis according
to the ICD 10. Moreover, a dementia syndrome was
diagnosed only if the MMSE score was below 25.
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In 2004, the definition of mild cognitive impairment
was improved by Winblad et al. [37,38]. MCI is the
most widely used classification for individuals who
have subjective memory or cognitive complaints, ob-
jective memory or cognitive impairments, and whose
activities of daily living are generally normal.
As pointed out in the introduction, the first clinical
sign of AD is impairment in episodic memory, more
specifically a deficit in delayed free recall. There are
several other neurological and cardiovascular diseases,
which show cognitive decline, but these do not specif-
ically affect episodic memory. In this study, we there-
fore decided to use a z-score of 6 −1.5 for wordlist
recall as a cut-off score to separate patients into groups
of amnesic or non-amnesic MCIs. Moreover, all MCI
patients had an MMSE score higher than 24. Classi-
fying patients as amnesic and non-amnesic MCI was
performed while being blind for the level of Aβ−1−42
and total tau in CSF (see below).
Determination of tau protein and Aβ1−42 in CSF
Lumbar punctures were performed between lumbar
vertebral body 4 and 5, by a trained neurologist, us-
ing a 22-gauge Sprotte spinal needle. Approximately
5 ml CSF was taken. CSF samples were free from any
blood contamination. It was collected in polypropylene
tubes and transported to an adjacent laboratory within
30 min. CSF samples were analyzed for cell count, to-
tal protein, lactate, glucose, IgG, IgA, IgM, Borrelioses
antibodies, Aβ1−42 and total tau protein. Apart from
the specimen used for the cell count, some CSF was
briefly centrifuged at low speed (4000 rpm for 7 min) to
pellet any cellular elements; these were stored at a tem-
perature of 4◦C (unfrozen) and analyzed within 7 days.
CSF total tau was determined quantitatively using a
commercial sandwich enzyme-linked immunosorbent
assay (Innotest hTAU-Ag, Innogenetics, Ghent, Bel-
gium). CSF Aβ1−42 was determined using a sand-
wich ELISA (Innotest β-amyloid 1−42, Innogenetics,
Ghent, Belgium). All tests for Aβ1−42 and total tau
were performed at the Medizinisches Labor Bremen
(Dr. A. Gerritzen) according to the recommendations
of the manufacturer Innogenetics.
Statistical evaluation
Neuropsychological assessment was based on age-
and education corrected z-scores (for the CERAD-NP)
and on age-corrected scores for most of the other neu-
ropsychological tests. In the statistical evaluation we
used the parametric Pearson correlation and we used a
p-value of p < 0.01 as criterion for significance for all
correlational analyses (which were performed as two-
sided tests, as usual). We tested for Group differences
in age, level of education, MMSE and BDI, using the
non-parametric Kruskal-Wallis Test, because of devi-
ations from the normal distribution. In the case of a
significant Group effect, we used the Mann-Whitney
U-Test for paired group comparisons. For the CSF
markers, we used an analysis of variance and t-tests for
analyzing group differences.
RESULTS
Demographic data
In this study, we recruited 36 patients with AD and
37 with MCI: Of the 36 patients with AD, 18 of them
had mild dementia (MMSE 18–24), 15 had moderate
dementia (MMSE 10–17), and 3 had a severe dementia
(MMSE< 10). Of the 37 patients with MCI 25 patients
showed an amnesic MCI and 12 a non-amnesic MCI.
There were no significant differences in age and educa-
tion between AD patients and amnesic MCIs patients,
but significantly more patients in the MCI group were
male compared to the AD patients. The non-amnesic
MCI group did not differ from the amnesic MCI and the
AD group in age, education, and gender distribution.
See for demographic details Table 1.
Mean total tau concentration was 665 ng/l for the
group of AD, 415 ng/l for the amnesic MCI group, and
285 ng/l for the non-amnesic MCI group. According to
Weimer & Fro¨hlich, the cut-off value for total tau in a
group of patients below the age of 71 years is 450 ng/l,
which fits with our data [39].
Aβ1−42 was 469 ng/l for AD patients, 661 ng/l for
amnesic MCI patients, and 813 ng/l for non-amnesic
MCIs. Clearly, both variables showed a wide range.
According to Blennow, the level of Aβ1−42 in CSF is
age independent and should be in AD patients about
50% of the value of healthy subjects [40]. This is
almost the case in our study.
The two MCI groups did not show significant dif-
ferences, but the AD group had a significantly higher
tau value than the amnesic MCI group (t: 2.347, p =
0.022) and the non-amnesic MCI group (t: −2.748,
p = 0.009). Moreover, Aβ1−42 was significantly de-
creased in this group compared to the MCI group (t:
−2.675, p = 0.01) and to the non-amnesic MCI group
(t: 4.134, p = 0.000).
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Table 2
Neuropsychological test results of the CERAD-ND test battery and additional tasks
AD amn-MCI Non amn-MCI
Mean SD Mean SD Mean SD
Word lexicon decision task 23.7 8.3 27.1 5.5 24.5 7.1
Phonological fluency 15.4 7.8 21.3 9.3 19.7 11.0
Digit span forward 5.9 2.1 6.3 2.3 6.2 2.0
Digit span backward 3.5 1.6 5.8 4.9 4.6 1.6
Cognitive speed (Zahlen-
Verbindungstest)
(seconds)
112.0 96.5 56.5 67.9 49.6 21.6
CERAD- NP∗
MMSE∗ −6.95 3.50 −2.40 1.39 −1.92 1.83
Semantic fluency∗ −2.22 1.08 −1.57 0.64 −1.24 1.09
Boston naming∗ −1.85 1.59 −0.70 1.12 0.23 0.83
Wordlist learning∗ −3.96 1.27 −2.29 0.88 −1.15 0.80
Wordlist delayed recall∗ −3.10 0.98 −2.10 0.86 −0.71 0.85
Wordlist intrusions∗ −0.70 1.33 −0.39 1.28 0.23 1.07
Wordlist savings∗ −2.19 1.36 −1.47 1.20 −0.15 0.93
Wordlist discrimination∗ −2.93 1.38 −1.81 0.99 0.00 1.30
Visuo-construction∗ −2.00 1.30 −0.93 2.04 −1.21 1.43
Visuo- construction recall∗ −2.67 0.78 −1.69 1.02 −1.10 1.17
Visuo- construction
savings∗
−2.54 0.96 −1.56 1.10 −0.74 1.13
∗age- and education corrected z-scores (for the CERAD-NP).
Neuropsychological assessment
For the neuropsychological test results, we refer to
Table 2. We found significant differences between the
amnesic and non-amnesic MCI groups for the Boston
naming test, word list learning, word list recall, word
list savings, word list recognition, and constructional
ability savings. We found significant differences be-
tween AD and MCI-groups for every task, as expect-
ed. Amnesic, but not non-amnesic MCIs, differed from
AD patients on the BDI (t: −2.226, p = 0.03), but
the average BDI score of 13.6 was in the range of mild
depressive symptoms.
CSF and neuropsychological investigation
We found no correlation at all between neuropsycho-
logical test scores and CSF markers in the AD group.
In the amnesic MCI group, the correlation between
Aβ1−42 and word list learning (r = 0.583, p = 0.002)
was significant. Cognitive speed (r = 0.507, p =
0.011), visuo-spatial memory performance (savings)
(r = 0.483, p = 0.014), and the MMSE z-score (r =
0.465, p = 0.019) just failed to reach the significance
criterion (p < 0.01). We found no significant correla-
tion between Tau and neuropsychological test results in
all three groups. See for detailed information Table 3.
The correlation plots for Aβ1−42 and wordlist learn-
ing illustrate the significant correlation for the amnesic
MCI group, but not for the other groups (Fig. 1A–
C). Although the correlation of cognitive speed and
Aβ1−42 just failed to become significant in the amnesic
MCI group, the correlation plot (Fig. 1D) suggests there
might be an association between cognitive speed and
Aβ1−42, but also that this association might be absent
in patients with already rather low Aβ1−42 levels.
Combining both MCI groups into one group and
looking for correlations between CSF markers and neu-
ropsychological functioning revealed three significant
results (p < 0.01): wordlist learning and Aβ1−42 (r =
0.491, p = 0.002), wordlist delayed recall and Aβ1−42
(r = 0.434,p = 0.007) and cognitive speed and Aβ1−42
(r = 0.443, p = 0.009).
DISCUSSION
We found a significant correlation between Aβ1−42
and memory performance in the amnesic MCI group.
No clear correlation was observed between Aβ1−42
and other cognitive tasks, neither in the amnesic MCI
group, nor in the non-amnesic MCI group. Finally,
there were no significant correlations between any of
the neuropsychological tests and Aβ1−42 (using age-
and education corrected z-scores) in the AD group.
The strong correlation between Aβ1−42-concentra-
tion in the CSF and memory performance in amnesic
MCI patients, but not in AD patients, indicates that
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Table 3
Correlation between Aβ1−42 and neuropsychological test results
AD amn-MCI n-amn-MCI
correlation p correlation p correlation p
MMSE ns 0.465∗ 0.019 ns
Word list learning ns 0.583∗∗ 0.002 ns
Cognitive speed (Zahlenverbindungstest) ns −0.507∗ 0.011 ns
Visuo-construction recall ns 0.422∗ 0.036 −0.635∗ 0.027
Visuo-construction savings ns 0.483∗ 0.014 −0.609∗ 0.036
Only test scores with at least one significant correlation are shown. Significant scores beyond the defined p < 0.01
are shown in italics and only for more complete information of the reader. ∗∗p < 0.01, ∗p < 0.05.
Fig. 1. A) Patients with AD, correlation between Aβ1−42 and wordlist learning (z-Scores); B) Patients with non-amnesic MCI, correlation
between Aβ1−42 and wordlist learning (z-Scores); C) Patients with amnesic MCI, correlation between Aβ1−42 and wordlist learning (z-Scores);
D) Patients with amnesic MCI, correlation between Aβ1−42 and cognitive speed (in seconds). Y-axis: Aβ1−42 in CSF (ng/l), X-axis: cognitive
performance.
specifically the decrease of Aβ1−42 in the CSF may re-
flect disease progression in AD during the early clinical
stage of the disease, i.e., the MCI stage. Although cog-
nitive speed just failed to reach the significance criteri-
on in the group of amnesic MCI, our data suggest such a
correlation, at least for the beginnings of the decline of
the Aβ1−42-concentration in the CSF. In the dementia
syndrome stage (MMSE< 25), the decrease of Aβ1−42
seems to have reached a plateau and subsequent func-
tional disease progression is related to processes like
cell death and increasing brain atrophy.
Our results correspond essentially with the model
proposed by Ingelsson et al. and the hypothetical mod-
el of dynamic biomarkers of the AD pathological cas-
cade of Jack et al. [5,6]. However, in contrast to these
models, our findings indicate that Aβ accumulation,
and subsequent concentration decline in CSF, seems to
be not yet in a steady state during early disease stages,
i.e., in MCI patients, but reaches a plateau level as the
patients show a clear-cut dementia syndrome. In our
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view, this difference in the time relation between cog-
nitive decline and CSF Aβ1−42 level is nevertheless
compatible with previous empirical studies. Ivanoiu &
Sindic [21] and Stomrud et al. [17] reported that a low
level of Aβ predicts cognitive decline in MCI patients.
Maccioni and coworkers [43] showed that Aβ1−42 level
correlates with cognitive performance in MCI patients
after dividing the patient group in different degrees of
impairment. In a recent study of Forsberg et al. [44],
which only involved memory testing and no other cog-
nitive tests, a correlation was found between Aβ1−42
level and memory performance in the MCI patients, but
not in the AD patients. Some studies failed to find sig-
nificant results [15,45], but they have used the MMSE,
and we have argued that the MMSE is not sensitive
enough for measuring early cognitive decline. It lacks
a proper test for episodic memory impairment, which
is the first and core sign of the beginning of AD. The
neuropathological changes leading to AD, therefore,
can be shown only using a sensitive episodic memory
tests as in the CERAD NP, (and, perhaps, having broad
population and education norms. Therefore we used
z-scores for the correlational analysis).
In a recent study, Stomrud et al. reported an associa-
tion of low CSF Aβ1−42 levels with impaired episodic
memory and reduced cognitive speed for healthy older
adults, features that are commonly observed in early
stages of pathological aging [46]. This may be inter-
preted according to the models of Ingelsson et al. [5]
and Jack et al. [6] as showing that Aβ1−42 accumula-
tion precedes the first clinical signs of AD. However,
our study replicates exactly the results of Stomrud et
al. [46] for amnesic MCI patients, that is, a correla-
tion between memory performance and cognitive speed
with the Aβ1−42 level. This pattern of results suggests
that the beginning of Aβ1−42 decline may start already
in a preclinical stage, and still progresses during the
MCI stage.
The distinction between amnesic and non-amnesic
MCI is not yet generally accepted, although there is
a consensus that memory disorders, especially of de-
layed recall, are the core feature of early AD [10–16].
We tried to reproduce our findings by combining both
MCI groups into one group. Again, Aβ1−42 (but not
tau) correlated with wordlist learning, but in this larger
group also with wordlist delayed recall and with cog-
nitive speed. Our results therefore hold for both, the
more specific (amnesic MCI) and the more general use
(MCI defined by any kind of cognitive impairment) of
this diagnostic entity.
We did not find any significant correlation between
the increase of tau in the CSF and neuropsychologi-
cal test performance. The relationship between neu-
ropathological changes and increase or decrease of
biomarkers in the CSF is not clarified in detail, but
the models of Ingelsson et al. and Jack et al. indicate
that in the first stages, disease progress is reflected in
a decrease of Aβ1−42, and in an advanced stage in an
increase of tau protein. In general, individuals from
our study population were in a relatively early clinical
stage, and even in the AD group, most patients showed
only a mild dementia. Possibly, a significant correla-
tion between tau protein and neuropsychological scores
can be proven only in later stages of the disease.
There may be yet another reason why we did not
find a correlation between neuropsychological test per-
formance and CSF tau protein, in contrast to previous
studies [19–21]. The increase of tau in the CSF might
be much slower than the decrease of Aβ1−42, contin-
uing longer into later stages of the disease. Buchhave
and colleagues published one of the few longitudinal
studies on tau and Aβ1−42 in patients with AD, MCI
and healthy controls with a follow-up of four years [48].
They found that only the tau level increases in AD and
that this increase is comparatively small (16%). To
demonstrate such a slow but steady increase of tau re-
quires the inclusion of large numbers of patients, and
this might very well explain the somewhat contradic-
tory results on the association between tau level and
cognitive decline in AD. A longitudinal study on mem-
ory performance and tau protein, using a large number
of patients in different disease stages, would probably
reveal such a correlation.
In the introduction, we suggested that Aβ1−42 might
correlate specifically with memory performance, be-
cause this is the hallmark in early stages of AD. Howev-
er, the widespread accumulation of Aβ1−42 containing-
plaques seems to be non-specifically distributed in the
brain, and this distribution pattern does not seem to
suggest a specific relation with memory performance.
Two considerations seem to be relevant here: First, the
correlation between cognitive speed and Aβ1−42 in the
CSF just missed the defined level of significance for
our group of amnesic MCIs. Together with the find-
ings of Molinuevo et al. [49] and Stomrud et al. [46],
this indicates that the Aβ1−42 level in CSF also cor-
relates with visual search, a typical temporo-parietal
function. Therefore, cognitive decline in preclinical
AD also involves cognitive functions other than episod-
ic memory. Second, there are also some indications,
that Aβ1−42 accumulation may disturb hippocampal
neuronal connections and memory performance specif-
ically. Mormino and collaborators demonstrated a re-
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lationship between Aβ deposition (as measured with
PIB imaging), hippocampal atrophy and episodic mem-
ory. They concluded that a decline in episodic mem-
ory in older individuals may be caused by Aβ1−42-
induced hippocampus atrophy, with Aβ1−42 deposi-
tion as the primary event in this cascade [50]. In line
with this explanation, longitudinal hippocampal vol-
ume losses in individuals with MCI appear to be close-
ly associated with a decrease in CSF Aβ1−42 levels
and increasing hyperphosphorylated tau [51]. More-
over, our results correspond with a recent study from
Petrie, in which correlations are shown between hy-
pometabolism in FDG-PET: Lower Aβ is associated
with hypometabolism, but only in the medial temporal
lobe, and higher tau concentration is associated with
hypometabolism in several brain regions [52].
There are some limitations of our study, which have
to be mentioned. First, an unrecognized variability of
the CSF marker might limit interpretation of the CSF
marker, because we did not investigate reproducibility
of the Innogenetic assays, which we used in this study.
It has been reported that the variability of measurement
is somewhat larger for Aβ1−42 than for tau. However,
innogenetic assay should be less prone to measurement
errors than other assays [47]. Moreover, in general,
an increased variability should reduce the correlation
coefficient, and should not produce spurious significant
results.
Second, we classified MCI patients as amnesic MCIs
on the basis of their scores on delayed recall and we
subsequently calculated the correlation between neu-
ropsychological test results and Aβ1−42 or tau. To
prevent this potential confounding, it would have been
better to classify patients in a way independent from
neuropsychological test scores, but that is hardly pos-
sible. It should also be noted that classification of MCI
patients was performed independently from the con-
centration of Aβ1−42 and tau, and delayed recall scores
also were not used for classifying AD patients.
Third, our study used a cross-sectional design and
therefore we do not know whether all of our amnesic
MCI are early AD patients. The rate of progression
from mild cognitive impairment to dementia varies
among authors and depends on different criteria for
classification. A three-year prospective study from
Palmer et al., for example, indicates that approximate-
ly two-third of the multiple domain-MCI patients and
half of the amnesic MCI patients progressed to AD [41,
42]. However, assuming that some of our amnesic MCI
patients do not have AD pathology, the correlation be-
tween memory performance and Aβ1−42 might even
by stronger than our results indicate.
In conclusion, we would like to argue that the de-
crease of Aβ1−42 in CSF mirrors disease progression
during the early stages up into AD, and it is there-
fore not restricted to the preclinical phase without any
functional symptoms. Aβ1−42 shows clear correlation
with memory performance and probably with cogni-
tive speed and visual search. The decrease of Aβ1−42
seems to reach a plateau in the state of dementia and
further functional disease progression is then related to
neurodegeneration without further reduction of Aβ1−42
in the CSF. The increase of tau seems to be much slow-
er and possibly extends over the entire period of the
progression into AD. Therefore, the inclusion of many
patients is required in order to evaluate the relationship
between Tau and neuropsychologicalperformance with
good accuracy.
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